Concepedia

Martin Zalesak

MZ

5

Publications

283

Citations

5

H-Index

2013

Active since

Affiliations

Novartis (United States)(Current)

Novartis (Switzerland)

Heinrich Heine University Düsseldorf

University of Pennsylvania

Centre d'Esclerosi Múltiple de Catalunya

Martin Zalesak is an author at Novartis (United States) specializing in hepatitis d, medicine, and health economics.

Top concepts

Publications per year

2013–2022

5

Publications

5

Higher Persistence in Newly Diagnosed Nonvalvular Atrial Fibrillation Patients Treated With Dabigatran Versus Warfarin

Martin Zalesak, Kimberly Siu, Kevin Francis et al. · Circulation Cardiovascular Quality and Outcomes · 2013 · 149 citations

Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study

Amit Bar‐Or, Heinz Wiendl, Xavier Montalbán et al. · Multiple Sclerosis Journal · 2021 · 59 citations · Full text

Current and Future Disease Progression of the Chronic HCV Population in the United States

Martin Zalesak, Kevin Francis, Alex Gedeon et al. · PLoS ONE · 2013 · 33 citations · Full text

, , +20

Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia: Phase 2 APOLITOS study

Jun‐ichi Kira, Jin Nakahara, Takayoshi Kurosawa et al. · Multiple Sclerosis Journal · 2021 · 28 citations

Serum Neurofilament Light Trajectories and Their Relation to Subclinical Radiological Disease Activity in Relapsing Multiple Sclerosis Patients in the APLIOS Trial

Amit Bar‐Or, Xavier Montalbán, Xixi Hu et al. · Neurology and Therapy · 2022 · 14 citations · Full text

Rows per page

1–5 of 5